Journal of Nephrology & Therapeutics

Clinical Research & Development, Kibow Biotech, Inc 4781 West Chester Pike, Newtown Square, PA 19073, USA

Publications

• Mini Review   
  Differentiating Sodium-Glucose Cotransporter 2 Inhibitors from Live Biotherapeutic Products (Probiotics) as Novel Therapeutic Intervention to Slow CKD Progression
  Author(s): Emmanuel Anteyi* and Natarajan Ranganathan
  
  Chronic kidney disease (CKD) is a global public health problem with high morbidity and mortality, from cardiovascular complications. CKD is a progressive and irreversible deterioration of kidney function with complex pathophysiological and pathogenetic pathways due to diverse etiologies and risk factors. Progression of CKD has a common complex and interrelated immunological and metabolic pathway resulting in inflammation and oxidative stress processes. This progression manifests clinically as irreversible functional and structural damage. The primary aim of therapeutic intervention in CKD management is delay progressive loss of function, and to prevent and manage complications. Recent approaches to slowing CKD progression include therapy with sodium-glucose cotransporter 2 inhibitor (SGLT2) and gut microbiome modulation with probiotics, based on beneficial clinical outcomes of metabol.. Read More»
  DOI: 10.37421/2161-0959.2022.12.415

  Abstract HTML PDF